Showing 3 posts of 3 posts found.


Acadia’s schizophrenia drug flops in Phase 3 trial

July 23, 2019
Manufacturing and Production acadia, clinical trials, menatl health, neuroscience, pharma, phase 3, schizophrenia

Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid …

US DoJ launch investigation into Acadia Pharmaceuticals

March 11, 2019
Sales and Marketing False Claims Act, SEC, acadia, antipsychotics, kickbacks

The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia …


FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug

March 30, 2016
Research and Development, Sales and Marketing FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis

Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) …

Latest content